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Abstract
HIV-specific T-lymphocyte responses that underlie IRIS are incomplete and largely remain
hypothetical. Of the several mechanisms presented by the host to control host immunological
damage, Treg cells are believed to play a critical role. Using the available experimental evidence, it
is proposed that enormous synthesis of conventional FoxP3- Th cells (responsive) often renders
subjects inherently vulnerable to IRIS, whereas that of natural FoxP3+  Treg cell synthesis
predominate among subjects that may not progress to IRIS. We also propose that IRIS non-
developers generate precursor T-cells with a high avidity to generate CD4+CD25+FoxP3+ Tregs
whereas IRIS developers generate T-cells of intermediate avidity yielding Th0 cells and effector T-
cells to mediate the generation of proinflammatory cytokines in response to cell-signaling factors
(IL-2, IL-6 etc.). Researchers have shown that IL-10 Tregs (along with TGF-β, a known anti-
inflammatory cytokine) limit immune responses against microbial antigens in addition to effectively
controlling HIV replication, the prime objective of HAART. Although certain technical limitations
are described herein, we advocate measures to test the role of Tregs in IRIS.
The hide and seek game in immune 
reconstitution inflammatory syndrome (IRIS): 
The factor?
The immune reconstitution inflammatory syndrome
(IRIS) in HIV-infected patients initiating highly active
antiretroviral therapy (HAART) leading to 'paradoxical
clinical worsening' [1] results from restored immunity to
specific infectious or non-infectious antigens [2-10]. Pos-
sible mechanisms include a partial recovery of the host
immune system or exuberant immunological responses to
antigenic stimuli. The overall frequency of IRIS is unde-
fined, but is believed to be dependent on underlying
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opportunistic infectious (mycobacteria, varicella zoster,
herpesviruses, and cytomegalovirus) and non-infectious
(autoimmune) burdens [2-10]. Of the subjects that are
initiated on HAART, only a proportion progress to
develop IRIS and the remaining never develop IRIS
despite an exuberant immune restoration from poor base-
line CD4+ T-cell levels. Recently, we proposed that sub-
jects that develop IRIS generate a high burden of
proinflammatory cytokines in response to enormous lev-
els of systemic bacterial LPS as compared with less LPS in
IRIS non-developers [11]. Although several other mecha-
nisms have been proposed, HIV-specific T-cell responses
underlying IRIS are incomplete [12]. To investigate the
inflammatory intermediaries of IRIS it will be crucial to
explain the intrinsic dynamics of immune cells after initi-
ating HAART [13]. Furthermore, factors that confers resist-
ance to development of IRIS among IRIS non-developers
needs to be described.
Possible role of memory T-cells in IRIS
The majority of individuals with HIV infection in
resource-constrained settings attend HIV testing centres
only after progression to terminal stage of HIV disease (i.e.
when their CD4+ T-cell counts are very low) [1,14]. There-
fore, these subjects with the most severe immunosuppres-
sion (CD4+ T-cell nadirs, 100 cells/μL), initiating
antiretroviral regimens may be at the highest risk for the
development of IRIS [15]. Conceptually, any individual
harboring microbial antigens should mount an over-exu-
berant immune response against any pre-existing antigen
(e.g. mycobacterial, cryptococcal, strongyloidal, etc.),
which at times may be detrimental to the host owing to
subsequent inflammatory reactions that follow the resto-
ration.
Reconstitution of memory cell responses is the initial hall-
mark of restoration of pathogen specific immune
responses after initiation of HAART. Recent evidence sug-
gests that the immune restoration following HAART is
characterized by enormous memory CD4+ T-cell types
(CD4+CD45RO+) likely due to peripheral lymphoid
redistribution [16,17]. A characteristic 2-phase increase in
CD4 T-cells occurs after initiating HAART; a rapid initial
increase in memory T cells in the first few months, fol-
lowed by a steady rise in naive T-cells that continue for
years with sustained therapy. Furthermore, recovery of
lost responses occurring during the early phase could also
be attributed to cellular redistribution rather than a de
novo specific CD4+ T-cell proliferation since naive acti-
vated CD4+ T-cells (CD4+CD45RA+CD62L+) do not
recover until after several months of therapy. The feature
and strength of this response may account the early-onset
of IRIS [3]. Moreover, an increase in the concentrations of
IFN-γ and IL-2 are reportedly responsible for this phe-
nomenon. There are a few studies to support the prolifer-
ation of peripheral blood mononuclear cells, antigen
specific CD4+ T-cells and IFN-γ response to Mycobacterium
tuberculosis  antigens after initiation of HAART in HIV-
infected patients [18,19]. The activated CD4+ T-cells are
subsequently primed to recognize previous antigenic
stimuli, and might account for the subsequent manifesta-
tions of IRIS. This, possibly could be due to the fact that
generation of post-HAART immune components always
arise from residual immune cells that had undergone
extensive immune activation rather than the newly syn-
thesized cells. Researchers have also shown that improve-
ment in antigen-specific T-cell restoration could be
attributed to an increase in memory CD4+ T-cell number
but not with increase in CD4+ T-cell number or decrease
in plasma viral load (PVL) [20]. Further, the study has
shown that improvement in delayed type hypersensitivity
(DTH) response was significantly associated only with a
decline in PVL [20].
IRIS developers vs IRIS non-developers: Are 
Tregs the determinants of inflammation after 
initiating HAART?
Of the several mechanisms put forth by the host to regu-
late immunological damage caused by over-exuberant
immune responses, Treg cells are believed to play a critical
role in regulating inflammatory responses by mediating
key components that facilitate immune suppression [21-
25]. Of the various Treg populations described, the
CD4+CD25+ and CD4+CD45RBlow cells function via the
action of IL-10 [26], cytotoxic T-cell-associated protein 4
(CTLA4) [27,28], and/or TGF-β [26-33], while other Tregs
secrete IL-10 [31-40] and TGF-β [41]. Tregs and naïve
helper T cells (Th0) are proposed to develop within a nor-
mal thymus through positive and negative selection proc-
esses. On the one hand, it is proposed that enormous
generation of conventional FoxP3-  Th cells (CD5low,
CD11alow, CD25low, CD38low, CD44low, CD45RBhigh,
CD54low, CD103ε low, GITRlow), that reportedly are paner-
gic to T-cell stimuli and non-suppressive, predominate
among subjects that are inherently vulnerable to IRIS. On
the other hand, the high turnover of natural FoxP3+ Treg
cells (CD5high, CD11ahigh, CD25high, CD38high, CD44high,
CD45RBlow, CD54high, CD103high, GITRhigh), that are con-
ventionally non-responsive to T-cell stimuli and suppres-
sive (normally beneficial, as it may help limit the severity
of tissue destruction associated with an inflammatory
condition due to infection), predominate among subjects
that may not progress to IRIS. Therefore, precursor T-cells
of relatively high avidity trigger Treg development via the
activation of Foxp3 (forkhead/winged-helix family tran-
scriptional repressor), whereas T-cell receptors of interme-
diate avidity yield conventional Th0 cells. We propose
that IRIS non-developers generate precursor T-cells with a
high avidity to generate CD4+CD25+FoxP3+ Tregs
whereas IRIS developers generate T-cells of intermediateJournal of Inflammation 2008, 5:2 http://www.journal-inflammation.com/content/5/1/2
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avidity yielding Th0 cells and effector T-cells to mediate
the generation of proinflammatory cytokines in response
to cell-signaling factors (IL-2, IL-6 etc.). We propose that
IRIS non-developers possess Foxp3+  in the naturally
occurring Tregs that inhibit CD4+  T-cell proliferation
through IL-10-independent, cell contact-dependent
mechanisms. This mechanism has already been demon-
strated in certain other inflammatory conditions. Besides
this, plasmacytoid dendritic cells (pDC) expressing ICOS
ligand (ICOS-L) appears to be responsible for the genera-
tion of IL-10 Tregs. Tregs are known to suppress cellular
proliferation and cytokine production by CD4+ and CD8+
T-cells in response to microbial antigens. Researchers have
shown that IL-10 levels are raised after HAART among
IRIS developers [13,42]. Furthermore, IL-10 Tregs also
limit immune responses against microbial antigens (M.
tuberculosis) in addition to controlling HIV replication
[42,43]. Tregs also suppress HIV-induced proliferation of
perforin-expressing CD8+ T-cells, which otherwise, could
mediate inflammation [42,44,45]. Both Th1 and Th2
responses can be controlled by IL-10 Tregs and by natu-
rally occurring Tregs [46]. It is to be remembered that Th1
cells producing IFN-γ are critical for obliterating intracel-
lular pathogens, notably M. tuberculosis and Listeria mono-
cytogenes, but are also implicated in inflammatory
pathologies [47,48]. Th2 cells, on the other hand, which
produce IL-4, IL-5, and IL-13, are important for the regu-
lation of immune responses to helminths but also cause
allergic pathologies [47,49]. IL-4 and IL-13 are implicated
in inhibiting the generation of proinflammatory
cytokines by macrophages [49]. In addition to being reg-
ulated by naturally occurring Tregs and by IL-10 Tregs,
Th1 and Th2 cells also reciprocally regulate the develop-
ment and function of each other. Because IL-10 is also
produced by B lymphocytes, macrophages, DCs and T
cells other than Tregs, it is clear that multiple cell types
could contribute to the regulation of host immune
responses via their production of IL-10. IL-10 is reported
to be essential in limiting immune responses to inflam-
mation [42,50]. Research on experimental animals has
shown that the deletion of IL-10 gene could facilitate sus-
ceptibility to inflammatory bowel disease and colitis
[49,50]. Thus regulation of the immune response may
occur at various levels, each utilizing different mecha-
nisms that, depending on the degree of inflammation and
the host response to infection, are called upon at different
stages during immune responses. The regulatory capacity
of antigen-driven IL-10 Tregs and of naturally occurring
Tregs and the induction of immunosuppressive cytokines
(IL-10 and TGF-β) provide a new level of immune regula-
tion to inhibit both Th1- and Th2-type immune responses
[50]. Treg fitness could be another possible approach that
appears to be of interest with regard to Treg levels in
chronic HIV disease. Although, we propose to test the
immunosuppressive role of Tregs in IRIS, we do foresee
certain limitations for testing the hypotheses. While CD4/
CD25/FoxP3 are well-cited markers for Tregs, there
appears to be a consensus in the flow cytometry commu-
nity on which markers actually define the Treg population
(activated and non-activated) in the presence of HIV
infection. Furthermore, Tregs are often reported to be few
in numbers in flow cytometric analyses and therefore in
the setting of HIV infection, it is questionable as to
whether the frequency of these cells is sufficient for testing
the proposed hypothesis. Future attempts using sophisti-
cated tools and technologies might render this possible.
We also warrant future research required to reveal the
mechanisms that underlie the possible role of APCs, effec-
tor molecules, such as IL-10 and TGF-β, secreted by Tregs
in determining the susceptibility of individuals to IRIS.
Conclusion
We propose to test whether IRIS non-developers generate
precursor T-cells with a high avidity to generate
CD4+CD25+FoxP3+ Tregs and whether IRIS developers
generate T-cells of intermediate avidity yielding Th0 cells
and effector T-cells. Although researchers have shown that
IL-10 Tregs control immune responses against foreign
antigens in addition to effectively controlling HIV replica-
tion, the prime objective of HAART, this needs to be inten-
sively investigated. Attempts have never been thrown to
reveal the role of tregs in IRIS and FoxP3 gene till date. The
hypothesis can be either tested in a disease-specific
approach (i.e. examining the role of Tregs in TB-IRIS sub-
jects) or by examining all forms of IRIS (both infectious
and non-infectious). In addition, the role of polymor-
phisms in TNF-α and IL-6 promotors can also be exam-
ined as these too could play a significant role in mediating
IRIS.
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